NNVC - NanoViricides, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
9.16
+2.54 (+38.37%)
At close: 4:00PM EST

8.98 -0.18 (-1.97%)
Pre-Market: 4:58AM EST

Stock chart is not supported by your current browser
Previous Close6.62
Open10.10
Bid8.91 x 900
Ask0.00 x 1400
Day's Range8.55 - 10.90
52 Week Range1.27 - 19.20
Volume16,212,495
Avg. Volume3,687,900
Market Cap67.995M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-2.12
Earnings DateFeb 19, 2020 - Feb 20, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.60
  • MarketWatch

    NanoViricides stock soars amid fears of global spread of COVID-19

    Shares of NanoViricides Inc. soared 33% in premarket trading Monday, after the antiviral therapies company, which previously announced it was working on a COVID-19 treatment, said it had sufficient funding for planned expenditures for this year. The company said it has reported that it has found "broad-spectrum virus-binding ligands" that are expected to attack COVID-19 at the same points that the virus uses to bind to cellular receptors as SARS-CoV. "It is well recognized that development of vaccines takes a long time, and that vaccines can often be ineffective against viruses due to viral mutations that lead to emergence of resistant strains," the company said in a statement. "It is also well recognized and well documented that monoclonal antibodies as antiviral drugs are very difficult to develop and often lead to emergence of resistant viral strains due to viral mutations." The stock has more than doubled (up 122%) over the past three months through Friday, while the S&P 500 has gained 7.3%.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 24, 2020: NNVC, WFC, SPCE, LL, CETX

    Benzinga Pro's Stocks To Watch For Monday NanoViricides (NNVC)  - Shares were up 30% ahead of the open as a continued increase in the number of coronavirus cases is the main headline impacting Wall Street ...

  • ACCESSWIRE

    NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2019 - Has Sufficient Cash, HerpeCide(TM) Drug Candidate IND Application Development in Progress

    SHELTON, CT / ACCESSWIRE / February 24, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its second quarter of financial year 2020 in a timely manner with the Securities and Exchange Commission. The Company reported that it had approximately $1.0 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.4M excluding a recent mortgage (described below), as of December 31, 2019, the end of the reporting period. The Company's expenditures were in line with budget estimates.

  • The Wuhan Virus and Research-Focused Biotech Companies
    GuruFocus.com

    The Wuhan Virus and Research-Focused Biotech Companies

    With the spread of the new coronavirus from Wuhan, investors should consider investing in smaller biotech and pharma players Continue reading...

  • ACCESSWIRE

    Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc.

    SHELTON, CT / ACCESSWIRE / February 12, 2020 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, reports that Dr. Makarand "Mak" Jawadekar, a veteran Pharma industry expert professional, has been duly appointed as an Independent Director to its Board of Directors. Dr. Mak Jawadekar has been serving as a strategic advisor to pharmaceutical and biotechnology companies through his independent consultancy since 2010.

  • ACCESSWIRE

    Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News

    SHELTON, CT / ACCESSWIRE / February 10, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that Dr. Anil Diwan, the Company's President and Executive Chairman of the Board, was interviewed on the Stuart Varney show on Fox Business News (FBN), on January 28, 2020. The Company has licensed a copy of the video excerpt from FBN and it is available on the Company's website (www.nanoviricides.com), home page, under the heading "Dr. Anil Diwan on Fox Business - 01/28/2020".

  • Can Biotech ETFs Continue to Soar in 2020?
    Zacks

    Can Biotech ETFs Continue to Soar in 2020?

    We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

  • ACCESSWIRE

    Nanoviricides President Dr. Diwan Was Interviewed By The Kennedy Show On Fox Business News

    SHELTON, CT / ACCESSWIRE / February 4, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that Dr. Anil Diwan, the Company's President and Executive Chairman of the Board, was interviewed on the Kennedy show on Fox Business News (FBN), on January 23, 2020. In discussing the recent Wuhan coronavirus (2019-nCoV) outbreak, Ms. Kennedy asked Dr. Diwan how such outbreaks can be treated, and how the nanoviricides technology can be harnessed for that effect.

  • Coronavirus update: 361 have died, there are now 11 cases in the U.S. and the case count has doubled SARS
    MarketWatch

    Coronavirus update: 361 have died, there are now 11 cases in the U.S. and the case count has doubled SARS

    U.S. health officials expanded the number of airports that U.S. citizens returning from China’s Hubei Province will be funneled through as part of the government’s efforts to stem the spread of the coronavirus.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 3, 2020: SYY, PCG, NNVC, UBER, TSLA

    Benzinga Pro's Stocks To Watch For Monday Sysco (SYY)  - Reported mixed Q2 results: beat on the bottom line but missed on the sales figure. Shares were up 0.5% ahead of the opening bell.  PG&E (PCG)  - ...

  • Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries
    MarketWatch

    Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries

    President Donald Trump’s coronavirus task force on Friday announced a series of actions aimed at stemming the spread of the coronavirus outbreaks, including declaring a public-health emergency in the U.S.

  • Benzinga

    The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...

  • ACCESSWIRE

    NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus

    SHELTON, CT / ACCESSWIRE / January 30, 2020 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is confirming public disclosures in articles by various industry journals and other articles, that it is working on developing a treatment for the novel coronavirus 2019-nCoV, or the Wuhan coronavirus. At this time, the Company does not have a collaboration with any of these agencies, and we have not been contacted by any of these entities or asked to develop a treatment for this virus. In fact it has been shown to use the same cell surface receptor as SARS-CoV, namely ACE2.

  • These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus
    GuruFocus.com

    These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus

    Anti-viral pharma companies catering to respiratory disorders performed solidly during the SARS outbreak, and history might repeat itself with this new virus Continue reading...

  • Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
    MarketWatch

    Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports

    A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.

  • Company News For Jan 28, 2020
    Zacks

    Company News For Jan 28, 2020

    Companies In The News Are:

  • Stock market news live: Stocks close lower as coronavirus death toll rises
    Yahoo Finance

    Stock market news live: Stocks close lower as coronavirus death toll rises

    Headlines moving the stock market in real time.

  • CDC officials say coronavirus is similar to SARS, no new U.S. cases reported
    MarketWatch

    CDC officials say coronavirus is similar to SARS, no new U.S. cases reported

    At least 110 people in 26 states have been identified as persons under investigation for coronavirus, Centers for Disease Control and Prevention officials said Monday.

  • Analyst: China's coronavirus victims 'probably 10 times' higher than reported
    Yahoo Finance

    Analyst: China's coronavirus victims 'probably 10 times' higher than reported

    As the number of patients stricken by China’s coronavirus continues to mount, at least one analyst believes the country’s reported casualty count might be far higher than Beijing has publicly admitted.

  • MarketWatch

    Vaccine, diagnostics stocks rise again on spreading coronavirus

    Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc. , up 42%; NanoViricides Inc. , up 29%; Allied Healthcare Products Inc. , up 22%; Inovio Pharmaceuticals Inc. , up 24%; and Novavax Inc. , up 13%. The Centers for Disease Control and Prevention said Sunday that there are now five confirmed cases in the U.S., all of whom had traveled to Wuhan, the city in China where the virus was first identified. Chinese health officials have said that more than 2,700 people have been sickened and at least 80 people died, according to The Wall Street Journal. Market concerns have sent global stocks and U.S. futures tumbling on Monday. The S&P 500 and the Dow Jones Industrial Average are both 1% over the last week.

  • ACCESSWIRE

    NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock

    SHELTON, CONNECTICUT / ACCESSWIRE / January 24, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has completed an underwritten public offering (the "Offering") with gross proceeds of $8.625 million before deducting underwriting discounts and other estimated offering expenses. The Offering included 2.5 million shares of the Company's common stock, and 375,000 additional shares from the exercise of the underwriter's option to purchase to cover over-allotments at the public offering price of $3.00 per share. The net proceeds to the Company after underwriter's commission and agreed upon customary fees and expenses were approximately $7.78 million, before deducting the Company's legal and accounting expenses related to the Offering.

  • ETF Trends

    Biotech ETFs Are Not Riding the Wave from Coronavirus Panic

    Despite concerns of a spreading coronavirus out of China, biotechnology stocks and sector-related ETFs are not enjoying the usual bump on hopes of developing new treatments to counter the contagion. Among the worst performing non-leveraged ETFs of Friday, the Virtus LifeSci Biotech Clinical Trials ETF (BBC) declined 3.4% and SPDR S&P Biotech ETF (XBI) decreased 3.2%. Meanwhile, the more broadly watched  iShares Nasdaq Biotechnology ETF (IBB) fell 2.5%.

  • Benzinga

    13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

    Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.

  • MarketWatch

    UPDATE: Vaccine stocks rise sharply as coronavirus fears mounts

    Shares of vaccine makers rose sharply again on Thursday, amid rising concerns about the outbreak of a new coronavirus in Wuhan, China that has led the authorities to quarantine the city of 11 million. Novavax Inx. , which developed a vaccine for MERS (Middle East respiratory syndrome) in 2013, gained 9% in early trade, while Moderna Inc. was up 2%. The company said it will work with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine to treat the new illness. Inovio Pharmaceuticals Inc. shares rose 9%, after that company said the CEPI has given it a grant of up to $9 million to develop a vaccine against the virus. NanoViricides , which rallied on the first reports of the news before falling back after it issued 2.5 million shares, soared 45%. The virus was first identified in December in Wuhan City, China. It has since sickened more than 599 people, including a U.S. resident who had traveled to Wuhan this month, according to the Centers for Disease Control and Prevention. China has reported 17 deaths. Health officials now believe the virus is spread human to human. The SPDR S&P Biotech ETF has gained 18% in the last 12 months, while the S&P 500 has gained 26%.

  • 3 Biotech Stocks Likely to Gain as Coronavirus Spreads
    Zacks

    3 Biotech Stocks Likely to Gain as Coronavirus Spreads

    Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.